Search

Your search keyword '"Olivier Scatton"' showing total 18 results
Start Over Author "Olivier Scatton" Journal journal of hepatology
18 results on '"Olivier Scatton"'

2. Nestin as a diagnostic and prognostic marker for combined hepatocellular-cholangiocarcinoma

Author

Julien Calderaro, Luca Di Tommaso, Pascale Maillé, Aurélie Beaufrère, Cong Trung Nguyen, Lara Heij, Viviane Gnemmi, Rondell P. Graham, Frédéric Charlotte, Suzanne Chartier, Dominique Wendum, Mukul Vij, Daniela Allende, Alba Diaz, Carla Fuster, Benjamin Rivière, Astrid Herrero, Jérémy Augustin, Katja Evert, Diego Francesco Calvisi, Wei Qiang Leow, Howard Ho Wai Leung, Jan Bednarsch, Emmanuel Boleslawski, Mohamed Rela, Anthony Wing-Hung Chan, Alejandro Forner, Maria Reig, Anaïs Pujals, Loetitia Favre, Manon Allaire, Olivier Scatton, Arnaud Uguen, Eric Trépo, Lukas Otero Sanchez, Denis Chatelain, Myriam Remmelink, Camille Boulagnon-Rombi, Céline Bazille, Nathalie Sturm, Benjamin Menahem, Eric Frouin, David Tougeron, Christophe Tournigand, Emmanuelle Kempf, Haeryoung Kim, Massih Ningarhari, Sophie Michalak-Provost, Jakob Nikolas Kather, Annette S.H. Gouw, Purva Gopal, Raffaele Brustia, Eric Vibert, Kornelius Schulze, Darius F. Rüther, Sören A. Weidemann, Rami Rhaiem, Jean-Charles Nault, Alexis Laurent, Giuliana Amaddeo, Hélène Regnault, Eleonora de Martin, Christine Sempoux, Pooja Navale, Jayendra Shinde, Ketan Bacchuwar, Maria Westerhoff, Regina Cheuk-Lam Lo, Mylène Sebbagh, Catherine Guettier, Marie Lequoy, Mina Komuta, Marianne Ziol, Valérie Paradis, Jeanne Shen, Stefano Caruso, Hôpital Henri Mondor, Istituto Clinico Humanitas [Milan] (IRCCS Milan), Humanitas University [Milan] (Hunimed), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Service de Pathologie [Hôpital Beaujon - APHP], Hôpital Beaujon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Molecular virology and immunology – Physiopathology and therapeutic of chronic viral hepatitis (Team 18) (Inserm U955), Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 (CANTHER), Institut Pasteur de Lille, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)-Centre National de la Recherche Scientifique (CNRS), CHU Lille, CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre de Recherche Saint-Antoine (CRSA), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), CHU Saint-Antoine [AP-HP], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Université de Montpellier (UM), Thérapies Laser Assistées par l'Image pour l'Oncologie - U 1189 (ONCO-THAI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona (UB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), CHU Henri Mondor [Créteil], Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Université libre de Bruxelles (ULB), CHirurgie, IMagerie et REgénération tissulaire de l’extrémité céphalique - Caractérisation morphologique et fonctionnelle - UR UPJV 7516 (CHIMERE), Université de Picardie Jules Verne (UPJV), Laboratoire de Signalisation et Récepteurs Matriciels (SiRMa), Matrice extracellulaire et dynamique cellulaire - UMR 7369 (MEDyC), Université de Reims Champagne-Ardenne (URCA)-SFR CAP Santé (Champagne-Ardenne Picardie Santé), Université de Reims Champagne-Ardenne (URCA)-Université de Reims Champagne-Ardenne (URCA)-Centre National de la Recherche Scientifique (CNRS)-Université de Reims Champagne-Ardenne (URCA)-SFR CAP Santé (Champagne-Ardenne Picardie Santé), Université de Reims Champagne-Ardenne (URCA)-Université de Reims Champagne-Ardenne (URCA)-Centre National de la Recherche Scientifique (CNRS), Imagerie et Stratégies Thérapeutiques des pathologies Cérébrales et Tumorales (ISTCT), Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Centre National de la Recherche Scientifique (CNRS), Département de Pathologie [CHU Caen], Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN), CHU Grenoble, Unité de recherche interdisciplinaire pour la prévention et le traitement des cancers (ANTICIPE), Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN)-Centre Régional de Lutte contre le Cancer François Baclesse [Caen] (UNICANCER/CRLC), Normandie Université (NU)-UNICANCER-Tumorothèque de Caen Basse-Normandie (TCBN)-UNICANCER-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de Chirurgie Viscérale et Digestive [CHU Caen], CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), Centre hospitalier universitaire de Poitiers (CHU Poitiers), Laboratoire d'Informatique Médicale et Ingénierie des Connaissances en e-Santé (LIMICS), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Université Sorbonne Paris Nord, Groupe Henri Mondor-Albert Chenevier, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Hôpital Albert Chenevier, Johns Hopkins University (JHU), Hôpital Claude Huriez [Lille], Physiopathologie et traitement des maladies du foie, Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Universitaetsklinikum Hamburg-Eppendorf = University Medical Center Hamburg-Eppendorf [Hamburg] (UKE), Centre Hospitalier Universitaire de Reims (CHU Reims), Génomique fonctionnelle des tumeurs solides = Functional Genomics of Solid Tumors [CRC] (FunGeST), Centre de Recherche des Cordeliers (CRC (UMR_S_1138 / U1138)), École Pratique des Hautes Études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Université Paris Cité (UPCité)-École Pratique des Hautes Études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Université Paris Cité (UPCité), Labex OncoImmunology, Equipe labellisée Ligue Contre le Cancer, Université Paris Descartes - Paris 5 (UPD5), Service d'Hépatologie [Avicenne], Hôpital Avicenne [AP-HP], Unité de Formation et de Recherche Santé, Médecine, Biologie Humaine [Bobigny], Université Paris 13 (UP13)-Sorbonne Paris Cité, Danmarks Tekniske Universitet = Technical University of Denmark (DTU), Centre Hospitalier Universitaire Vaudois [Lausanne] (CHUV), Génomique Fonctionnelle des Tumeurs Solides (U1162), Université Paris 13 (UP13)-Université Paris Diderot - Paris 7 (UPD7)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Crosscope, University of Michigan [Ann Arbor], University of Michigan System, AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre), Hôpital Bicêtre, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service d’Anatomie Pathologique [CHU Beaujon], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Beaujon [AP-HP], Labex Immuno-oncology [Paris] ( Université Paris Descartes - Paris 5 - PRES Sorbonne Paris Cité), Université Paris Descartes - Paris 5 (UPD5)-PRES Sorbonne Paris Cité, Service d'Anatomie et cytologie pathologiques [CHU Saint-Antoine], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Service d'Anatomie et cytologie pathologiques = Service de Pathologie [CHU Pitié-Salpêtrière] (ACP), CHU Henri Mondor, Service d'Hépato-Gastro-Entérologie [CHU Pitié-Salpêtrière], Université de Reims Champagne-Ardenne (URCA)-Université de Picardie Jules Verne (UPJV)-Université de Reims Champagne-Ardenne (URCA)-Université de Picardie Jules Verne (UPJV)-Centre National de la Recherche Scientifique (CNRS)-Université de Reims Champagne-Ardenne (URCA)-SFR CAP Santé (Champagne-Ardenne Picardie Santé), Université de Reims Champagne-Ardenne (URCA)-Université de Picardie Jules Verne (UPJV)-Université de Reims Champagne-Ardenne (URCA)-Université de Picardie Jules Verne (UPJV)-Centre National de la Recherche Scientifique (CNRS), École pratique des hautes études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Université Paris Cité (UPCité)-École pratique des hautes études (EPHE), Service d'Hépato-gastro-entérologie [CHU Saint-Antoine], and Groningen Institute for Organ Transplantation (GIOT)

Subjects
Carcinoma, Hepatocellular, Hepatology, combined hepatocellular-cholangiocarcinoma, Liver Neoplasms, hepatocellular carcinoma, liver, Prognosis, Nestin, Cholangiocarcinoma, Bile Ducts, Intrahepatic, Bile Duct Neoplasms, cancer, Humans, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract

Background & Aims: Combined hepatocellular-cholangiocarcinoma (cHCC-CCA) is a rare primary liver cancer (PLC) associated with a poor prognosis. Given the challenges in its identification and its clinical implications, biomarkers are critically needed. We aimed to investigate the diagnostic and prognostic value of the immunohistochemical expression of Nestin, a progenitor cell marker, in a large multicentric series of PLCs.Methods: We collected 461 cHCC-CCA samples from 32 different clinical centers. Control cases included 368 hepatocellular carcinomas (HCCs) and 221 intrahepatic cholangiocarcinomas (iCCAs). Nestin immunohistochemistry was performed on whole tumor sections. Diagnostic and prognostic performances of Nestin expression were determined using receiver-operating characteristic curves and Cox regression modeling.Results: Nestin was able to distinguish cHCC-CCA from HCC with AUCs of 0.85 and 0.86 on surgical and biopsy samples, respectively. Performance was lower for the distinction of cHCC-CCA from iCCA (AUCs of 0.59 and 0.60). Nestin, however, showed a high prognostic value, allowing identification of the subset of cHCC-CCA (“Nestin High”, >30% neoplastic cells with positive staining) associated with the worst clinical outcome (shorter disease-free and overall survival) after surgical resection and liver transplantation, as well as when assessment was performed on biopsies.Conclusion: We show in different clinical settings that Nestin has diagnostic value and that it is a useful biomarker to identify the subset of cHCC-CCA associated with the worst clinical outcome. Nestin immunohistochemistry may be used to refine risk stratification and improve treatment allocation for patients with this highly aggressive malignancy. Lay summary: There are different types of primary liver cancers (i.e. cancers that originate in the liver). Accurately identifying a specific subtype of primary liver cancer (and determining its associated prognosis) is important as it can have a major impact on treatment allocation. Herein, we show that a protein called Nestin could be used to refine risk stratification and improve treatment allocation for patients with combined hepatocellular carcinoma, a rare but highly aggressive subtype of primary liver cancer.

Published
2021
Full Text
View/download PDF

3. Predictive factors of tumor recurrence after liver transplantation for hepatocellular carcinoma: analysis of a multicenter prospective study including 371 patients

Author

Thomas Decaens, René Adam, Sébastien Dharancy, Laurent Sulpice, Didier Samuel, Emmanuel Boleslawski, Marianne Latournerie, Georges-Philippe Pageaux, Olivier Scatton, Sylvie Radenne, Eric Savier, Claire Francoz, Claire Vanlemmens, Pierre-Henri Bernard, Jean Hardwigsen, Jean Gugenheim, Christophe Duvoux, and Nadia Oubaya

Subjects
Hepatology
Published
2022
Full Text
View/download PDF

4. Benchmark performance of laparoscopic left lateral sectionectomy and right hepatectomy in expert centers

Author

F.-R. Pruvot, C. Hobeika, S Truant, Patrick Pessaux, M.-A. Allard, M Tedeschi, Kayvan Mohkam, A. Sa Cunha, Julio Abba, J Chauvat, Riccardo Memeo, Takayuki Kawai, Christian Ducerf, T Codjia, François Paye, N Oudafal, Alexis Laurent, J Nunèz, F Jehaes, Takeo Nomi, M Chirica, Jean-Yves Mabrut, A Mulliri, C VanBrugghe, David Fuks, J Barbieux, Ephrem Salamé, Eric Vibert, L Ferre, Y.P. Le Treut, Oriana Ciacio, F R Souche, Emmanuel Boleslawski, A Thobie, Z Cherkaoui, Daniel Cherqui, S Okumura, M Bougard, B Trechot, Shohei Komatsu, M. El Amrani, Olivier Soubrane, J.-M. Regimbeau, F Muscari, L Chiche, E Buc, J.-M. Fabre, M Lesurtel, B Suc, Brice Gayet, B Menahem, P. Balladur, O Turini, A.-R. Kianmanesh, Nicolas Golse, François Cauchy, Emilie Gregoire, J Ewald, J Hardwigsen, J.-Y. Mabrut, Claire Goumard, C Ratajczak, Edouard Girard, P Leourier, L. Schwarz, J Zemour, Christian Letoublon, Gabriella Pittau, Guillaume Passot, Christophe Laurent, E Lermite, Jean-Marc Regimbeau, A Carmelo, G Millet, X Unterteiner, D Patrice, U Marchese, A. Laurent, J Lubrano, Lionel Rebibo, H Fagot, K Lecolle, T Hor, Olivier Scatton, Petru Bucur, René Adam, N Petrucciani, and Louise Barbier

Subjects
0301 basic medicine, Male, Percentile, medicine.medical_specialty, medicine.medical_treatment, Patient Readmission, Resection, 03 medical and health sciences, 0302 clinical medicine, Postoperative Complications, medicine, Hepatectomy, Humans, In patient, Blood Transfusion, Mortality, Severe complication, Quality Indicators, Health Care, Hepatology, business.industry, General surgery, Liver Neoplasms, Margins of Excision, Odds ratio, Composite indicator, Length of Stay, Hospitals, Benchmarking, 030104 developmental biology, Outcome and Process Assessment, Health Care, Health Care Surveys, 030211 gastroenterology & hepatology, Female, Laparoscopy, France, Benchmark, laparoscopic liver resection, left lateral sectionectomy, quality of care, right hepatectomy, textbook outcome, Complication, business
Abstract

Background & Aims Herein, we aimed to establish benchmark values – based on a composite indicator of healthcare quality – for the performance of laparoscopic left lateral sectionectomy (LLLS) and laparoscopic right hepatectomy (LRH) using data from expert centers. Methods Data from a nationwide multicenter survey including all patients undergoing LLLS and LRH between 2000 and 2017 were analyzed. Textbook outcome (TO) completion was considered in patients fulfilling all 6 of the following characteristics: negative margins, no transfusion, no complication, no prolonged hospital stay, no readmission and no mortality. For each procedure, a cut-off laparoscopic liver resection (LLR) volume by center was associated with TO on multivariable analysis. These cut-offs defined the expert centers. The benchmark values were set at the 75th percentile of median outcomes among these expert centers. Results Among 4,400 LLRs performed in 29 centers, 855 patients who underwent LLLS and 488 who underwent LRH were identified. The overall incidences of TO after LLLS and LRH were 43.7% and 23.8%, respectively. LLR volume cut-offs of 25 LLR/year (odds ratio [OR] 2.45; bootstrap 95% CI 1.65–3.69; p = 0.001) and 35 LLR/year (OR 2.55; bootstrap 95% CI 1.34–5.63; p = 0.003) were independently associated with completion of TO after LLLS and LRH, respectively. Eight centers for LLLS and 6 centers for LRH, including 516 and 346 patients undergoing LLLS/LRH respectively, reached these cut-offs and were identified as expert centers. After LLLS, benchmark values of severe complication, mortality and TO completion were defined as ≤5.3%, ≤1.2% and ≥46.6%, respectively. After LRH, benchmark values of severe complication, mortality and TO completion were ≤20.4%, ≤2.8% and ≥24.2%, respectively. Conclusions This study provides an up-to-date reference on the benchmark performance of LLLS and LRH in expert centers. Lay summary In a nationwide French survey of laparoscopic liver resection, expert centers were defined according to the completion of a textbook outcome, which is a composite indicator of healthcare quality. Benchmark values regarding intra-operative details and outcomes were established using data from 516 patients with laparoscopic left lateral sectionectiomy and 346 patients with laparoscopic right hepatectomy from expert centers. These values should be used as a reference point to improve the quality of laparoscopic resections.

Published
2020

7. NAFLD and liver transplantation: Current burden and expected challenges

Author

Olivier Scatton, Filomena Conti, Raluca Pais, Thomas M. Runge, Yvon Calmus, Thierry Poynard, Vlad Ratziu, A. Sidney Barritt, and Pascal Lebray

Subjects
0301 basic medicine, medicine.medical_specialty, Carcinoma, Hepatocellular, medicine.medical_treatment, Disease, Liver transplantation, Chronic liver disease, Gastroenterology, Article, 03 medical and health sciences, Liver disease, 0302 clinical medicine, Non-alcoholic Fatty Liver Disease, Risk Factors, Internal medicine, Humans, Medicine, Intensive care medicine, Hepatology, business.industry, Liver Neoplasms, Fatty liver, nutritional and metabolic diseases, medicine.disease, digestive system diseases, Liver Transplantation, Europe, 030104 developmental biology, Diabetes Mellitus, Type 2, Hepatocellular carcinoma, 030211 gastroenterology & hepatology, Metabolic syndrome, Steatohepatitis, business
Abstract

Because of global epidemics of obesity and type 2 diabetes, the prevalence of non-alcoholic fatty liver disease (NAFLD) is increasing both in Europe and the United States, becoming one of the most frequent causes of chronic liver disease and predictably, one of the leading causes of liver transplantation both for end-stage liver disease and hepatocellular carcinoma. For most transplant teams around the world this will raise many challenges in terms of pre- and post-transplant management. Here we review the multifaceted impact of NAFLD on liver transplantation and will discuss: (1) NAFLD as a frequent cause of cryptogenic cirrhosis, end-stage chronic liver disease, and hepatocellular carcinoma; (2) prevalence of NAFLD as an indication for liver transplantation both in Europe and the United States; (3) the impact of NAFLD on the donor pool; (4) the access of NAFLD patients to liver transplantation and their management on the waiting list in regard to metabolic, renal and vascular comorbidities; (5) the prevalence and consequences of post-transplant metabolic syndrome, recurrent and de novo NAFLD; (6) the alternative management and therapeutic options to improve the long-term outcomes with particular emphasis on the correction and control of metabolic comorbidities.

Published
2016
Full Text
View/download PDF

8. Establishment of an ex vivo model of human fibrotic liver slices culture: characterization of intrahepatic immune cells and TH17 cytokines

Author

Jesintha Gaston, Jean-Christophe Vaillant, P. Stanislas, Sylvie Lagaye, Vladimir A. Morozov, Olivier Scatton, and D. Kartasheva

Subjects
0301 basic medicine, Hepatology, business.industry, 05 social sciences, Cell biology, 03 medical and health sciences, 030104 developmental biology, Immune system, 0502 economics and business, Medicine, 050211 marketing, business, Th17 cytokines, Ex vivo
Published
2018
Full Text
View/download PDF

9. Insulin receptor isoform A is a new player in the progression of hepatocellular carcinoma

Author

Françoise Praz, Olivier Rosmorduc, C. Yves, Z. Salame, Laetitia Fartoux, Olivier Scatton, Dominique Wendum, Christèle Desbois-Mouthon, Fatiha Merabtene, Eva Benabou, Sylvana Tahraoui, Laura Fouassier, and Marie Lequoy

Subjects
Gene isoform, Insulin receptor, Hepatology, biology, business.industry, Hepatocellular carcinoma, medicine, biology.protein, Cancer research, medicine.disease, business
Published
2018
Full Text
View/download PDF

11. PS-191-External validation of an algorithm combining multi-analyte blood tests (FibroTest-LCR1-LCR2) for identifying subjects at risk of hepatocellular carcinoma among patients with chronic liver disease

Author

Olivier Scatton, Thierry Poynard, Valentina Peta, Pierre Nahon, Vlad Ratziu, Angela Sutton, Frédéric Charlotte, An Ngo, Tam Thanh Pham, Yen Ngo, Marianne Ziol, Imbert-Bismut Francoise, Mona Munteanu, Olivier Deckmyn, Chantal Housset, Olivier Lucidarme, and Dominique Thabut

Subjects
medicine.medical_specialty, Hepatology, business.industry, FibroTest, Hepatocellular carcinoma, Internal medicine, External validation, medicine, medicine.disease, business, Chronic liver disease, Gastroenterology, Multi analyte
Published
2019
Full Text
View/download PDF

12. FRI-399-Impact of a temporary cardiac arrest in a brain dead liver donor on liver transplantation results

Author

Rousseau Geraldine, Eric Savier, Yann De-Rycke, Olivier Scatton, Filomena Conti, Meriem Khalfallah, Frédéric Charlotte, Corinne Vezinet, Perdigao Fabiano, and Elodie Timsit

Subjects
Brain dead, Pathology, medicine.medical_specialty, Hepatology, business.industry, medicine.medical_treatment, Liver donors, medicine, Liver transplantation, business
Published
2019
Full Text
View/download PDF

13. Might physicians be restricting access to liver transplantation for patients with alcoholic liver disease?

Author

Valerie Perut, Olivier Scatton, Olivier Soubrane, Gwenaëlle Vidal-Trecan, Yvon Calmus, and Filomena Conti

Subjects
medicine.medical_specialty, Alcoholic liver disease, Cirrhosis, Attitude of Health Personnel, medicine.medical_treatment, Alcoholic hepatitis, Liver transplantation, Gastroenterology, Health Services Accessibility, Primary biliary cirrhosis, Surveys and Questionnaires, Internal medicine, medicine, Humans, Liver Diseases, Alcoholic, Response rate (survey), Hepatology, Liver Cirrhosis, Biliary, business.industry, Patient Selection, Refusal to Treat, Odds ratio, medicine.disease, Confidence interval, Liver Transplantation, Cross-Sectional Studies, France, business
Abstract

Background/Aims In France, the most common cause of cirrhosis is excessive alcohol consumption. Post-transplant survival rates in patients with alcoholic liver disease (ALD) are at least as good as those seen with other indications. However, fewer of these patients are found on the waiting list. To understand the reasons for this discrepancy, it was decided to examine physicians' attitudes concerning the allocation of deceased donor liver allografts. Methods Using a standardized postal questionnaire, 1739 physicians were asked to allocate 100 liver transplants to two competing groups of patients who were equivalent except for the cause of their cirrhosis (i.e. alcohol-related or primary biliary cirrhosis). A composite score was then used to assess their attitude regarding the behavior of alcoholics and their responsibility for their illness. Results Among the 475 respondents (response rate: 27.3%), 55.2% allocated fewer than 50 transplants to ALD patients. This lower rate was independently associated with factors such as being a general practitioner (odds ratio [OR]=3.2, 95% confidence interval [95%CI]=1.8–5.9), a misinterpretation of ALD patients being equivalent to others (OR=1.8, 95%CI=1.1–3.0) or unfavorable attitudes regarding alcoholics (OR=4.0, 95%CI=1.7–9.5, to OR=126.8, 95%CI=34.0–472.1). Conclusions Greater information and education of physicians may improve access to liver transplantation for ALD patients.

Published
2009
Full Text
View/download PDF

14. Factors associated with tumor recurrence after liver transplantation for hepatocellular carcinoma: prospective cohort on 371 patients

Author

Olivier Scatton, René Adam, Marianne Latournerie, Jacques Belghiti, C. Vanlemens, S. Radenne, Christophe Duvoux, Sébastien Dharancy, Didier Samuel, Georges Philippe Pageaux, N. Oubaya, Thomas Decaens, Eric Savier, Emmanuel Boleslawski, and Laurent Sulpice

Subjects
Oncology, medicine.medical_specialty, Hepatology, business.industry, Hepatocellular carcinoma, Internal medicine, medicine.medical_treatment, Medicine, Liver transplantation, business, medicine.disease, Prospective cohort study, Tumor recurrence
Published
2017
Full Text
View/download PDF

16. Prospective assessment of renal histopathological lesions in patients with end-stage liver disease: effects on long-term renal function after liver transplantation

Author

Olivier Soubrane, Olivier Scatton, Corinne Antoine, Dominique Nochy, Denis Glotz, Gary S. Hill, Filomena Conti, Yvon Calmus, Philippe Cluzel, and Evangeline Pillebout

Subjects
medicine.medical_specialty, Pathology, Cirrhosis, medicine.medical_treatment, Renal function, Liver transplantation, urologic and male genital diseases, Gastroenterology, Severity of Illness Index, Nephropathy, Nephrotoxicity, End Stage Liver Disease, chemistry.chemical_compound, Liver disease, Internal medicine, medicine, Humans, Diabetic Nephropathies, Prospective Studies, Hematuria, Creatinine, Hepatology, business.industry, Glomerulonephritis, IGA, medicine.disease, Liver Transplantation, Transplantation, Proteinuria, chemistry, Asymptomatic Diseases, business, Follow-Up Studies
Abstract

The incidence of organic renal lesions in patients with end-stage liver disease is unknown. The goal of this study was to make a prospective evaluation of renal histological lesions in a group of unselected patients awaiting liver transplantation.Sixty cirrhotic patients underwent a renal biopsy via the transjugular route. The potential effect of renal lesions on renal function was evaluated five years after transplantation.The yield of biopsies enabling satisfactory analysis was 77%, and no major complications occurred. Proteinuria0.5 g/day was observed in only 8.7% of these patients, microscopic haematuria in 4.3%, creatinine levels133 mmol/L (1.5mg/dl) in 10.9%, and Modification of the Diet in Renal Disease (MDRD) clearance60 ml/min in 13.0%. Twenty-five patients (55.3%) had a morphological diagnosis of renal disease, 15 displayed IgA nephropathy and immunofluorescence testing showed that 12 had specific diabetic linear staining for IgG and albumin, of whom seven had associated histological lesions of diabetic nephropathy. Five years after liver transplantation, renal function had significantly deteriorated more in patients with initial diabetic lesions than in those with normal histology or IgA nephropathy alone.In patients with end-stage liver disease, IgA nephropathy and diabetic lesions were frequently found despite the absence of renal impairment and/or urinalysis anomalies. Our results strongly suggest that severe renal failure develops preferentially in liver transplant recipients with diabetes or carbohydrate intolerance, and that pre-existing arterial lesions may favour the nephrotoxicity of calcineurin inhibitors. Diabetes prior to transplantation needs to be strictly managed and requires a renal sparing immunosuppressive regimen after transplantation.

Published
2011

17. 665 CULTURE OF HEPATITIS C VIRUS (HCV) IN PRIMARY HUMAN ADULT HEPATOCYTES: A PHYSIOLOGICAL MODEL FOR THE PRODUCTION OF AUTHENTIC INFECTIOUS PARTICLES

Author

Philippe Podevin, Céline Hernandez, Arnaud Carpentier, J.-F. Méritet, Ralf Bartenschlager, Sylvie Demignot, Filomena Conti, Olivier Scatton, Vanessa Calle, Yvon Calmus, Véronique Pène, Arielle R. Rosenberg, Takaji Wakita, and Lynda Aoudjehane

Subjects
Physiological model, Primary (chemistry), Hepatology, Hepatitis C virus, medicine, Biology, medicine.disease_cause, Virology
Published
2010
Full Text
View/download PDF

18. Inhibition of receptor-interacting protein kinase 1 improves experimental non-alcoholic fatty liver disease

Author

Amine Majdi, Bruno Fève, Gilles Courtois, Tawhidul Islam, Tatiana Ledent, Tounsia Aït-Slimane, Taïeb Mestiri, Olivier Scatton, Florine Ballenghien, Jean-Louis Delaunay, Fabienne Foufelle, Laura Fouassier, Marta B. Afonso, Carina Prip-Buus, Marthe Moldes, Filomena Conti, Chantal Housset, Marie Lagouge, Axelle Cadoret, Cecília M. P. Rodrigues, Lynda Aoudjehane, Jérémie Gautheron, Vlad Ratziu, Laboratoire de Biologie Cellulaire, UPRES 1833, Service d'Hépato-Gastro-Entérologie [CHU Pitié-Salpêtrière], CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut de génétique et biologie moléculaire et cellulaire (IGBMC), Université Louis Pasteur - Strasbourg I-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre de Recherche des Cordeliers (CRC), Université Paris Diderot - Paris 7 (UPD7)-École pratique des hautes études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre de Recherche Saint-Antoine (UMRS893), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Trafic Membranaire et Signalisation Dans les Cellules Epitheliales, Centre de Mathématiques Laurent Schwartz (CMLS), Centre National de la Recherche Scientifique (CNRS)-École polytechnique (X), Service d'Endocrinologie, diabétologie et endocrinologie de la reproduction [CHU Saint-Antoine], CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Institut Cochin (IC UM3 (UMR 8104 / U1016)), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Institute of cardiometabolism and nutrition (ICAN), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Pathologies biliaires, fibrose et cancer du foie [CHU Saint-Antoine], Centre de Recherche Saint-Antoine (CR Saint-Antoine), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-CHU Saint-Antoine [AP-HP], Service d'Hépato-Gastroentérologie [CHU Pitié-Salpêtrière], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Pitié-Salpêtrière [APHP], Université Paris Diderot - Paris 7 (UPD7)-École pratique des hautes études (EPHE)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Pierre et Marie Curie - Paris 6 (UPMC), École polytechnique (X)-Centre National de la Recherche Scientifique (CNRS), Service d'Endocrinologie, Diabétologie et d'Endocrinologie de la Reproduction [CHU Saint-Antoine], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Saint-Antoine [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [APHP]-Sorbonne Université (SU), Pathologies biliaires, fibrose et cancer du foie (Inserm UMR_S 938), CHU Saint-Antoine [APHP]-Centre de Recherche Saint-Antoine (CR Saint-Antoine), and Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)

Subjects
Male, Necroptosis, Diet, High-Fat, Gene Knockout Techniques, Mice, 03 medical and health sciences, Liver disease, 0302 clinical medicine, Non-alcoholic Fatty Liver Disease, Fibrosis, medicine, Animals, Humans, Protein Kinase Inhibitors, ComputingMilieux_MISCELLANEOUS, Aged, 030304 developmental biology, Mice, Knockout, Liver injury, Acrylamides, Sulfonamides, 0303 health sciences, Hepatology, business.industry, Fatty liver, nutritional and metabolic diseases, Middle Aged, medicine.disease, digestive system diseases, 3. Good health, Mice, Inbred C57BL, Disease Models, Animal, Treatment Outcome, Mitochondrial respiratory chain, Liver, Receptor-Interacting Protein Serine-Threonine Kinases, 030220 oncology & carcinogenesis, Hepatocytes, Cancer research, Female, Steatosis, Steatohepatitis, business, Protein Kinases, [SDV.AEN]Life Sciences [q-bio]/Food and Nutrition, MLKL, NAFLD, NASH, RIPK1, Signal Transduction
Abstract

Background & Aims In non-alcoholic fatty liver disease (NAFLD), hepatocytes can undergo necroptosis: a regulated form of necrotic cell death mediated by the receptor-interacting protein kinase (RIPK) 1. Herein, we assessed the potential for RIPK1 and its downstream effector mixed lineage kinase domain-like protein (MLKL) to act as therapeutic targets and markers of activity in NAFLD. Methods C57/BL6J-mice were fed a normal chow diet or a high-fat diet (HFD). The effect of RIPA-56, a highly specific inhibitor of RIPK1, was evaluated in HFD-fed mice and in primary human steatotic hepatocytes. RIPK1 and MLKL concentrations were measured in the serum of patients with NAFLD. Results When used as either a prophylactic or curative treatment for HFD-fed mice, RIPA-56 caused a downregulation of MLKL and a reduction of liver injury, inflammation and fibrosis, characteristic of non-alcoholic steatohepatitis (NASH), as well as of steatosis. This latter effect was reproduced by treating primary human steatotic hepatocytes with RIPA-56 or necrosulfonamide, a specific inhibitor of human MLKL, and by knockout (KO) of Mlkl in fat-loaded AML-12 mouse hepatocytes. Mlkl-KO led to activation of mitochondrial respiration and an increase in β-oxidation in steatotic hepatocytes. Along with decreased MLKL activation, Ripk3-KO mice exhibited increased activities of the liver mitochondrial respiratory chain complexes in experimental NASH. In patients with NAFLD, serum concentrations of RIPK1 and MLKL increased in correlation with activity. Conclusion The inhibition of RIPK1 improves NASH features in HFD-fed mice and reverses steatosis via an MLKL-dependent mechanism that, at least partly, involves an increase in mitochondrial respiration. RIPK1 and MLKL are potential serum markers of activity and promising therapeutic targets in NAFLD. Lay summary There are currently no pharmacological treatment options for non-alcoholic fatty liver disease (NAFLD), which is now the most frequent liver disease. Necroptosis is a regulated process of cell death that can occur in hepatocytes during NAFLD. Herein, we show that RIPK1, a gatekeeper of the necroptosis pathway that is activated in NAFLD, can be inhibited by RIPA-56 to reduce not only liver injury, inflammation and fibrosis, but also steatosis in experimental models. These results highlight the potential of RIPK1 as a therapeutic target in NAFLD.

Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results